[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"machineMD AG\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":82},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100612794","safety-and-normative-data-with-neos-100612794",false,"NCT07258212","Safety and Normative Data With Neos™","Safety and Normative Data With Neos™, in Healthy Volunteers, Children and Patient Populations With Ophthalmological or Neurological Disease","neos-SNOW","Inclusion Criteria Healthy Volunteers:\n\n* Age \\> 3\n* Informed consent by participant and\u002For legal representative documented per signature\n* Snellen visual acuity ≥ +0.1 LogMAR, with correction, on both eyes\n* Refractive error between -10 and +5 diopters, on both eyes\n\nExclusion Criteria Healthy Volunteers:\n\n* Known ophthalmological, neurological or vestibular disease\n* Current medication\u002Fdrugs that could potentially influence performance in ocular motor tasks and\u002For compliance in the judgement of the investigator (e.g. benzodiazepines, alcohol, or stimulants)\n* Stimulative medication (e.g. with Ritalin®)\n* Known substance abuse\n\nInclusion Criteria Patients:\n\n* Age \\> 3\n* Informed consent by participant and\u002For legal representative, designated trusted person or next of kin, documented per signature\n* Refractive error between -10 and +5 diopters, on both eyes\n* Known ophthalmological or neurological disease\n\nExclusion Criteria Patients:\n\n* Visual acuity in one or both eyes \\\u003C +1.3 LogMAR\n* Incapacity to understand and comply with the examination in the opinion of the investigator (e.g. due to very advanced dementia, with failure to comply with easy experimental instructions and tasks)\n* Known substance abuse",true,"ALL","3 Years",{"count":21,"type":22},200,"ESTIMATED","1 Day","OBSERVATIONAL","The goal of this clinical study is to collect standard data for the medical device neos™.\n\nneos™ is a system that shows images and measures the resulting eye movements and pupil size.\n\nCollecting standard data involves three steps. First it is checked if neos™ eye-tracking works well. Eye-tracking means recording where a person is looking. After that it is checked if participants look at the images shown in neos™ as planned. Finally the eye movements and the pupil size are measured. This is done in healthy volunteers including children and persons with eye and brain problems.\n\nParticipants in the study will wear a virtual reality headset. The screens in the headset will show different images. Cameras in the headset will record eye movements and pupil size. This will take about 15 minutes. During these 15 minutes the investigator looks at the following behaviors of the participants eyes:\n\n* Where are the eyes looking\n* How do the pupils react to light and darkness\n* How do the eyes move\n* How much can the participant see from the corner of their eyes\n* How well are the eyes working together",[27],"Neuro-Ophthalmology",[29,30,31,32,33,34,35,36,37,38],"Virtual reality","Visual field","Ocular alignment","Afferent pupillary function","Efferent pupillary function","Smooth pursuit","Saccades","Gaze holding","Fusional amplitude","Normative data","RECRUITING","2025-11-27",{"date":42,"type":43},"2025-12-02","ACTUAL",{"date":45,"type":43},"2024-03-07",{"date":47,"type":22},"2026-06",{"name":49,"class":50},"machineMD AG","INDUSTRY",3,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":58,"targetDuration":60,"studyType":24,"phases":4,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},"100567103","development-of-digital-diagnostic-devices-for-parkinsons-disease-100567103","NCT06663826","Development of Digital Diagnostic Devices for Parkinson's Disease","Inclusion Criteria:\n\n* Diagnosis of Parkinson's disease or of another parkinsonian syndrome (atypical Parkinson's)\n* Refractive error between -6 and +4 diopters, on both eyes\n* Informed consent by participant documented per signature\n* Able to self-report history of daily gait freezing and\u002For festination\n* Able to walk unsupported or using an aid for at least 5 minutes and if over 69 used to carrying out this level of exercise\n\nExclusion Criteria:\n\n* Other known neurological diseases\n* Current medication\u002Fdrugs that could potentially influence performance in ocular motor tasks and\u002For compliance in the judgement of the investigator (e.g. benzodiazepines, alcohol, stimulants, or recreational drugs) - except Parkinson's medications\n* Incapacity to understand and comply with the examination (e.g. due to advanced cognitive decline, failure to comply with easy experimental instructions and tasks)\n* Any injury or disorder that may affect eye movement measurements or balance (other than Parkinson's or referring primary condition)\n* Any skin conditions or broken skin in the calf and behind the knee area\n* Lack of access or limited connectivity to WiFi in home setting",{"count":59,"type":22},100,"15 Days","In this project, ocular motor, pupil and gait data in people with Parkinson's disease (PD) will be collected in order to develop machine learning models for the diagnosis and monitoring of PD. With this, the investigators aim to advance the state of the art in PD diagnosis and monitoring. By integrating the principles of machine learning with high-quality sensor data, more accurate and earlier diagnosis could potentially be achieved. Ocular motor and pupil data will be collected with the standard clinical examination and with neos, a medical device approved for objective ocular motor and pupil measurement. Gait will be collected using an IMU sensor and GaitQ senti, a consumer device that allows for an objective and continuous remote gait monitoring.",[63],"Parkinson Disease",[65,66,67,68,69,70,71,72],"Parkinson's disease","oculomotor","ocular motor","gait","eye movements","pupil","virtual reality headset","eye tracking","2025-10-02",{"date":75,"type":43},"2025-10-07",{"date":77,"type":43},"2024-10-01",{"date":79,"type":22},"2026-06-30",{"name":49,"class":50},1,""]